Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2016

Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report providescomprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
- The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AlbireoPharma Alnylam Pharmaceuticals, Inc. Aquinox Pharmaceuticals Inc. Arbutus Biopharma Corporation Arisaph Pharmaceuticals, Inc. AstraZeneca Plc BiOrion Technologies B.V. Bird Rock Bio, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Can-Fite BioPharma Ltd. Cardax Pharmaceuticals, Inc. Cerenis Therapeutics Holding SA Conatus Pharmaceuticals Inc. Connexios Life Sciences Pvt. Ltd. Daiichi Sankyo Company, Limited Dr. Falk Pharma GmbH DURECT Corporation Dynavax Technologies Corporation Enanta Pharmaceuticals, Inc. Exicure, Inc. F. Hoffmann-La Roche Ltd. Galectin Therapeutics, Inc. Galmed Pharmaceuticals Ltd. Genfit SA GenKyoTex S.A. Gilead Sciences, Inc. Immuron Limited Intercept Pharmaceuticals, Inc. Inventiva SAS Ionis Pharmaceuticals, Inc. Jenrin Discovery, Inc. Kissei Pharmaceutical Co., Ltd. Kyorin Pharmaceutical Co., Ltd. Medivation, Inc. Merck & Co., Inc. Metabolic Solutions Development Company, LLC Naia Limited NGM Biopharmaceuticals, Inc. Nimbus Therapeutics, LLC Nippon Chemiphar Co., Ltd. Nitto Denko Corporation Novartis AG NovaTarg Therapeutics, Inc Novo Nordisk A/S Pharmaxis Limited Promethera Biosciences S.A. ProMetic Life Sciences Inc. Protalix BioTherapeutics, Inc. Regulus Therapeutics Inc. Shire Plc Stelic Institute & Co., Inc. TaiwanJ Pharmaceuticals Co., Ltd. Therapix Biosciences Ltd Tobira Therapeutics, Inc. Vascular Biogenics Ltd. Verlyx Pharma Inc. Verva Pharmaceuticals Limited Viking Therapeutics, Inc. Virobay Inc. Zafgen Inc. Zydus Cadila Healthcare Limited


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###